大幸药品加码中国市场，正露丸门店将达8万家

Core Viewpoint - The company Daikokuten Pharmaceutical aims to significantly expand the sales of its coated tablet "Zengluwan Kangfu Zhixie Pian" in China, targeting a growth in store presence and sales revenue by 2028 [2][4]. Group 1: Sales Expansion Strategy - Daikokuten Pharmaceutical plans to increase the number of stores selling its main products, including "Zengluwan," from approximately 14,000 to 25,200 by the fiscal year 2027 [2]. - The company aims to double its pharmaceutical sales revenue in the Chinese market to approximately 1.7 billion yen by the fiscal year 2028, compared to the expected revenue for the fiscal year 2025 [2][4]. - The sales strategy will reflect regional characteristics, focusing on areas with high acceptance of traditional medicine, such as South China, while also targeting urban areas like Shanghai and Beijing that prefer Western medicine [5]. Group 2: Product Recognition and Marketing - "Zengluwan Kangfu Zhixie Pian," introduced to the Chinese market in 2011, has gained recognition among younger consumers due to its mild scent and ease of use, leading to anticipated continued growth in sales [2][4]. - The company plans to enhance brand awareness through advertising in subways and on television, aiming to adjust the sales ratio of "Zengluwan" and "Zengluwan Kangfu Zhixie Pian" from the current 9:1 to an equal share [7]. - The company is addressing supply shortages caused by the COVID-19 pandemic by extending factory operating hours and increasing personnel, with a goal of stabilizing supply by the fiscal year 2026 [7].